Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Protagenic Therapeutics Inc (PTIXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PTIXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -66.67% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 13650 | Beta 0.44 | 52 Weeks Range 0.00 - 0.04 | Updated Date 03/15/2025 |
52 Weeks Range 0.00 - 0.04 | Updated Date 03/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -94.91% | Return on Equity (TTM) -231.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5822414 |
Shares Outstanding - | Shares Floating 5822414 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Protagenic Therapeutics Inc
Company Overview
History and Background
Protagenic Therapeutics Inc. is a biopharmaceutical company focused on developing novel therapies for neurological and inflammatory diseases. More specific information on the founding year, milestones, and evolution is not readily available in public sources.
Core Business Areas
- Neurological Therapies: Development of peptide-based therapeutics targeting neurodegenerative diseases.
- Inflammatory Disease Therapies: Development of therapies focused on inflammation.
Leadership and Structure
Specific details on leadership and organizational structure are not readily available in public sources.
Top Products and Market Share
Key Offerings
- PT-121: A peptide therapeutic for neurological disorders. Specific market share, number of users, or revenue data is not publicly available. Competitors depend on the specific indication being pursued. This could include companies with treatments for diseases like Parkinson's or Alzheimer's.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. It is also an industry with large potential returns for successful products.
Positioning
Protagenic Therapeutics Inc. is a smaller player focused on peptide-based therapies. Specific competitive advantages are not readily available without further information.
Total Addressable Market (TAM)
The TAM for neurological and inflammatory disease treatments is substantial, estimated in the billions of dollars annually. Protagenic's positioning within this TAM depends on the success of its pipeline and its ability to secure funding and partnerships.
Upturn SWOT Analysis
Strengths
- Novel peptide-based therapeutic approach
- Focus on unmet medical needs
- Potential for targeted therapies
Weaknesses
- Limited financial resources
- Early-stage pipeline
- Dependence on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to address additional indications
- Breakthrough Therapy designations for novel treatments
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
Competitive Landscape
Without specific market share data, it's impossible to make a comparison.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is not publicly available.
Future Projections: Future growth projections are unavailable without analyst coverage or company guidance.
Recent Initiatives: Recent strategic initiatives are not publicly available.
Summary
Protagenic Therapeutics Inc. is a biopharmaceutical company with a focus on neurological and inflammatory diseases, utilizing a peptide-based therapeutic approach. Its success hinges on its early-stage pipeline advancements and securing strategic partnerships. The company faces risks from clinical trial outcomes, competition, and regulatory hurdles, which affects their financials.
Similar Companies
Sources and Disclaimers
Data Sources:
- Company website (if available)
- Publicly available news articles and press releases
- Industry reports
Disclaimers:
The information provided is based on limited publicly available data and should not be considered investment advice. Financial information may be inaccurate or unavailable.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagenic Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-04-27 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.protagenic.com |
Full time employees 1 | Website https://www.protagenic.com | ||
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.